Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Performance comparison between infrared molecular fingerprint (IMF) information, and diagnostically established lung-cancer markers for predicting lung cancer patients’ survival performed on the same patients’ blood samples

From: Assessing lung cancer progression and survival with infrared spectroscopy of blood serum

Parameter

C-index Markers

C-index IMFs

# Patients

IMFs

 

0.63 \(\pm\) 0.12

160

Stage

0.67 \(\pm\) 0.16

0.68 \(\pm\) 0.12

95

NSE

0.64 \(\pm\) 0.15

0.65 \(\pm\) 0.12

132

CEA

0.59 \(\pm\) 0.18

0.66 \(\pm\) 0.12

147

CYFRA-21-1

0.72 \(\pm\) 0.10

0.68 \(\pm\) 0.10

144

Hemoglobin

0.57 \(\pm\) 0.10

0.64 \(\pm\) 0.09

159

Leukocytes

0.63 \(\pm\) 0.12

0.64 \(\pm\) 0.09

159

  1. The number of patients varies across evaluations since not all blood-based parameters were obtained for all of the 160 patients that were included in the cohort study. Therefore, the IMF evaluation for the largest population is given first (n:160), with further comparisons of IMF’s performance with different established analytes (on smaller sample sets). The comparison is performed by evaluating Harrell’s C-index on trained Cox regression models within a 10-fold cross-validation
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us